Abstract
The Omicron variant of SARS-CoV-2 is causing a rapid increase in infections in various countries. This new variant of concern carries an unusually high number of mutations in key epitopes of neutralizing antibodies on the spike glycoprotein, suggesting potential immune evasion. Here we assessed serum neutralizing capacity in longitudinal cohorts of vaccinated and convalescent individuals, as well as monoclonal antibody activity against Omicron using pseudovirus neutralization assays. We report a near-complete lack of neutralizing activity against Omicron in polyclonal sera after two doses of the BNT162b2 vaccine, in convalescent individuals, as well as resistance to different monoclonal antibodies in clinical use. However, mRNA booster immunizations in vaccinated and convalescent individuals resulted in a significant increase of serum neutralizing activity against Omicron. Our study demonstrates that booster immunizations will be critical to substantially improve the humoral immune response against the Omicron variant.
Competing Interest Statement
H.G., K.V., and F.Kl. are listed as inventors on pending patent application(s) on SARS-CoV- 2-neutralizing antibodies filed by the University of Cologne.
Funding Statement
This work was supported by grants from COVIM: NaFoUniMedCovid19 (FKZ: 01KX2021) (to L.E.S. and F.Kl.), the Federal Institute for Drugs and Medical Devices (V-2021.3 / 1503_68403 / 2021-2022) (to F.Ku. and L.E.S.), by the German Center for Infection Research (DZIF) (to F.Kl.), and the DFG CRC1279 and CRC1310 (to F.Kl.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
COVID-19-convalescent samples were obtained under protocols approved by the ethics committee (EC) of the Medical Faculty of the University of Cologne (16-054 and 20-1187). Samples from non-infected vaccinated individuals were obtained under protocols (EICOV, COVIMMUNIZE, and COVIM) approved by the EC of Charite - Universitaetsmedizin Berlin (EA4/245/20 and EA4/244/20; EICOV and COVIMMUNIZE), and by the Federal Institute for Vaccines and Biomedicines (Paul Ehrlich Institute) and the EC of the state of Berlin (COVIM).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are included in the figure, table, and supplement of this manuscript.
